BRIEF-Tempus Announces a Collaboration with Verastem to Develop CDx for First-Ever FDA-Approved KRAS-Mutant Recurrent Low-Grade Serous Ovarian Cancer Combination Treatment

Reuters
20 May
BRIEF-Tempus Announces a Collaboration with <a href="https://laohu8.com/S/VSTM">Verastem</a> to Develop CDx for First-Ever FDA-Approved KRAS-Mutant Recurrent Low-Grade Serous Ovarian Cancer Combination Treatment

May 20 (Reuters) - Tempus AI Inc TEM.O:

  • TEMPUS AI : PARTNERS WITH VERASTEM TO DEVELOP CDX FOR FDA-APPROVED KRAS-MUTANT RECURRENT LOW-GRADE OVARIAN CANCER COMBINATION TREATMENT

Source text: ID:nBwTjLjNa

Further company coverage: TEM.O

((Reuters.Briefs@thomsonreuters.com;))

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10